Finance

Lists
Outlook: 55.6% bullish·11.1% bearish
Go to analysis
ELV:NYSE
Elevance Health Inc
$429.48
-0.04%
(-0.17) 1D
$432.36
+0.67% (+2.88)
After hours
Closed: Nov 11, 4:00:02 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ELV...
Open
$428.94
High
$430.54
Low
$422.00
Mkt. cap
90.37B
Avg. vol.
1.38M
Volume
698.26K
52-wk high
$450.69
52-wk low
$274.84
Beta
0.63
Shares outstanding
216.06M
No. of employees
97K
Open
$428.94
High
$430.54
Low
$422.00
Mkt. cap
90.37B
Avg. vol.
1.38M
Volume
698.26K
52-wk high
$450.69
52-wk low
$274.84
Beta
0.63
Shares outstanding
216.06M
No. of employees
97K
News stories
From web sources and news partners
Profile
Elevance Health, Inc. is an American health insurance company. Prior to June 2022, Elevance Health was named Anthem, Inc. The company is the world's seventh largest healthcare company based on revenue. Its services include medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans through affiliated companies such as Anthem Blue Cross and Blue Shield, Anthem Blue Cross in California, Wellpoint, and Carelon. It is the largest for-profit managed health care company in the Blue Cross Blue Shield Association. As of 2022, the company had 46.8 million members within its affiliated companies' health plans. Based on its 2021 revenues, the company ranked 20th on the 2022 Fortune 500. In 2023, the company's seat in the Forbes Global 2000 rankings was 78. Carelon Global Solutions, Elevance Health's Business Process Outsourcing /Shared Services subsidiary, serves the group's offshore and customer service management. It operates sites in India, Puerto Rico, Philippines, and the United States. Wikipedia
About Elevance Health Inc
CEOGail Koziara Boudreaux
Employees96.6K
Founded1944
HeadquartersIndianapolis, Indiana, United States
SectorHealth Care
IndustryHealth care provider
Websiteelevancehealth.com
Analyst ratings
Based on 14 analysts giving stock ratings to ELV in the past 3 months
Buy
Buy
9
Hold
5
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for ELV in the last 3 months.
Highest
Current $429.48
$523.00 (+21.78%)
Average
$479.85 (+11.73%)
Lowest
$406.00 (-5.47%)
Analyst
Recommendation
Action
Price target
Projected
Date
Lance Wilkes
Bernstein
Buy
Maintained
$520.00
+21.1%
11/04/2026
Stephen Baxter
Wells Fargo
Buy
Reiterated
$492.00
+14.6%
10/27/2026
Ryan Langston
TD Cowen
Buy
Maintained
$495.00
+15.3%
10/23/2026
Ann Hynes
Mizuho Securities
Buy
Maintained
$490.00
+14.1%
10/23/2026
Scott Fidel
Goldman Sachs
Hold
Maintained
$451.00
+5%
10/22/2026
David S Macdonald
Truist Financial
Buy
Maintained
$500.00
+16.4%
10/22/2026
A.J. Rice
UBS
Buy
Reiterated
$523.00
+21.8%
10/22/2026
Erin Wright
Morgan Stanley
Hold
Maintained
$449.00
+4.5%
10/22/2026
Ben Hendrix
RBC Capital
Hold
Maintained
$455.00
+5.9%
10/21/2026
Jason Cassorla
Guggenheim
Buy
Maintained
$485.00
+12.9%
10/21/2026
Michael Ha
Robert W. Baird
Hold
Maintained
$406.00
-5.5%
10/22/2026
Kevin Fischbeck
Bank of America Securities
Buy
Reiterated
$500.00
+16.4%
10/22/2026
Andrew Mok CFA
Barclays
Buy
Maintained
$472.00
+9.9%
10/22/2026
David Toung
Argus Research
Hold
Maintained
-
-
08/20/2026
Whit Mayo
Leerink Partners
Hold
Reiterated
$395.00
-8%
07/17/2026
David Windley
Jefferies
Buy
Maintained
$450.00
+4.8%
07/16/2026
Amit Daryanani
Evercore ISI
Hold
Maintained
-
-
07/15/2026
Sarah James
Cantor Fitzgerald
Buy
Maintained
$450.00
+4.8%
07/07/2026
Lisa Gill
J.P. Morgan
Buy
Maintained
$476.00
+10.8%
06/08/2026
George Hill
Deutsche Bank
Buy
Upgraded
$498.00
+16%
05/20/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Upgraded
$360.00
-16.2%
05/19/2026
Last report
Oct 21, 2026
Fiscal period
Q3 2026
$6.99 / $4.69
+48.89%beat
Revenue / Est. (USD)
51.43B / 49.16B
+4.61%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
49.75B
50.18B
50.47B
51.43B
Cost of goods sold
38.06B
35.62B
37.02B
37.78B
Cost of revenue
38.06B
35.62B
37.02B
37.78B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.75B
11.66B
11.04B
11.37B
Operating expense
10.92B
11.78B
11.15B
11.48B
Total operating expenses
48.98B
47.39B
48.17B
49.26B
Operating income
766.00M
2.79B
2.30B
2.17B
Other non operating income
-
-
-
-
EBT including unusual items
215.00M
2.30B
1.94B
1.79B
EBT excluding unusual items
399.00M
2.43B
1.94B
1.81B
Income tax expense
-331.00M
544.00M
483.00M
451.00M
Effective tax rate
-153.95%
23.61%
24.94%
25.14%
Other operating expenses
-
-
-
-
Net income
547.00M
1.76B
1.46B
1.36B
Net profit margin
1.10%
3.52%
2.90%
2.65%
Earnings per share
3.33
12.58
7.45
6.99
Interest and investment income
-
-
-
-
Interest expense
-367.00M
-357.00M
-364.00M
-358.00M
Net interest expenses
-367.00M
-357.00M
-364.00M
-358.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.17B
3.14B
2.67B
2.53B
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps